473 related articles for article (PubMed ID: 18722004)
21. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
22. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
23. Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer.
Wu JC; Hakama M; Anttila A; Yen AM; Malila N; Sarkeala T; Auvinen A; Chiu SY; Chen HH
Breast Cancer Res Treat; 2010 Jul; 122(2):553-66. PubMed ID: 20054645
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
Koong SL; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
[TBL] [Abstract][Full Text] [Related]
26. [Screening for ovarian cancer].
Bjørge T; Dørum A; Tropé CG
Tidsskr Nor Laegeforen; 2000 May; 120(12):1444-8. PubMed ID: 10851943
[TBL] [Abstract][Full Text] [Related]
27. Statistical considerations in cancer screening programs.
Prorok PC; Connor RJ; Baker SG
Urol Clin North Am; 1990 Nov; 17(4):699-708. PubMed ID: 2120836
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
Tsoi KK; Ng SS; Leung MC; Sung JJ
Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
[TBL] [Abstract][Full Text] [Related]
29. Influence of reproductive factors on mortality after epithelial ovarian cancer diagnosis.
Robbins CL; Whiteman MK; Hillis SD; Curtis KM; McDonald JA; Wingo PA; Kulkarni A; Marchbanks PA
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2035-41. PubMed ID: 19589914
[TBL] [Abstract][Full Text] [Related]
30. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
Gerson L; Lin OS
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates.
Roberts DN; Arguedas MR; Fallon MB
Liver Transpl; 2007 Feb; 13(2):206-14. PubMed ID: 17205561
[TBL] [Abstract][Full Text] [Related]
32. Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis.
Jewell EL; Kulasingam S; Myers ER; Alvarez Secord A; Havrilesky LJ
Gynecol Oncol; 2007 Dec; 107(3):532-40. PubMed ID: 17900674
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women.
Taneja C; Edelsberg J; Weycker D; Guo A; Oster G; Weinreb J
J Am Coll Radiol; 2009 Mar; 6(3):171-9. PubMed ID: 19248993
[TBL] [Abstract][Full Text] [Related]
34. [Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].
Wang Q; Jin PH; Lin GW; Xu SR; Chen J
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):135-9. PubMed ID: 12697117
[TBL] [Abstract][Full Text] [Related]
35. An interim determination of health gain from oral cancer and precancer screening: 2. Developing a model of population screening.
Downer MC; Jullien JA; Speight PM
Community Dent Health; 1997 Dec; 14(4):227-32. PubMed ID: 9458580
[TBL] [Abstract][Full Text] [Related]
36. The effect of service screening on breast cancer mortality rates.
Cox B
Eur J Cancer Prev; 2008 Aug; 17(4):306-11. PubMed ID: 18562953
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of screening strategies for Gonorrhea among females in private sector care.
Bernstein KT; Mehta SD; Rompalo AM; Erbelding EJ
Obstet Gynecol; 2006 Apr; 107(4):813-21. PubMed ID: 16582117
[TBL] [Abstract][Full Text] [Related]
38. The value of mammography in different ethnic groups in Israel--analysis of mortality reduction and costs using CAN*TROL.
Rennert G
Cancer Detect Prev; 1991; 15(6):477-81. PubMed ID: 1723656
[TBL] [Abstract][Full Text] [Related]
39. High participation rates are not necessary for cost-effective colorectal cancer screening.
Howard K; Salkeld G; Irwig L; Adelstein BA
J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121
[TBL] [Abstract][Full Text] [Related]
40. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.
Aletti GD; Podratz KC; Moriarty JP; Cliby WA; Long KH
Gynecol Oncol; 2009 Jan; 112(1):16-21. PubMed ID: 19027146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
